source
- AbbVie halts development of livmoniplimab after deeming benefit limitedAbbVie announced it is discontinuing the phase 2 development of its monoclonal antibody livmoniplimab (ABBV-151) after concluding the drug is unlikely to outperform existing therapies. The drug wa…
- Bayer CEO says company is negotiating a most-favored-nation trade pact with US administrationBayer chief executive Bill Anderson announced the drugmaker is actively pursuing a most-favored-nation (MFN) agreement with the United States. The comment signals that Bayer is in talks with the T…